Welcome!

News Feed Item

2012: Sweeping Advances Made In MS Research

Part 1: Overview, Progress Toward Stopping MS   

NEW YORK, Dec. 26, 2012 /PRNewswire-USNewswire/ -- MS research continued to advance on many fronts in 2012. This year saw:

(Logo: http://photos.prnewswire.com/prnh/20090302/DC77093LOGO)

  • The approval of a second oral therapy for relapsing forms of MS and other emerging treatments progressing through the development pipeline;
  • The launch of the International Progressive MS Collaborative, the largest effort to date to speed research to stop progressive forms of MS;
  • The discovery of what could be a target of the immune attack in people with MS may lead to new understanding of the disease and new treatment strategies;
  • The completion of the first human trial of an experimental therapy targeting myelin repair;
  • Progress in restoring functions using innovative rehabilitation techniques, including memory enhancement using a technique involving stories and imagery to solidify learning, and improving balance and mobility with specific exercises;and
  • Advances in uncovering MS triggering factors, bringing us closer to finding ways to prevent the disease; and many other advances pushing us closer to a world free of MS.

The National MS Society continues to propel research forward with a comprehensive strategy aimed at stopping MS, restoring function and ending MS forever (http://www.nationalmssociety.org/research/index.aspx):

In the world's largest meeting dedicated to MS research, over 7,000 scientists convened in Lyon, France to present findings at ECTRIMS (European Committee for Treatment and Research in MS). Over 1250 studies covering virtually every aspect of research were presented:

View videos on specific ECTRIMS topics http://www.youtube.com/playlist?list=PLnPWMdCPZiBbT4OEEunsWbzFTkWNoguQD&feature=addto

PROGRESS TOWARD STOPPING MS

The Society continued to invest in research to stop MS, including:

  • Funding of clinical trials:
    • Testing whether vitamin D, or the sex hormone estriol, or the probiotic approach of a sports drink containing parasite eggs, can reduce MS immune attacks
    • Determining if treatments available for other disorders, such as riluzole (a treatment for ALS or Lou Gehrig's disease) or phenytoin (a treatment for epilepsy), or the antioxidants lipoic acid or green tea extract, can protect the nervous system from damage.
    • Supporting a syndicate formed in the United Kingdom to conduct innovative clinical trials of neuroprotective drugs in secondary-progressive MS.
  • New projects focusing on discovering "biomarkers" to aid better diagnosis and treatment decisions;
  • Collaboration in a cross-disease drug screening initiative aimed at discovering the potential of compounds to stop nerve degeneration and protect the brain from harm;
  • In partnership with Merck Serono, Fast Forward provided funding for lab research to discover small molecules that can deliver therapies to areas of nervous system damage and protect against that damage in MS.

Other important 2012 results toward stopping MS include:

Treatment Pipeline

FDA Approves Oral Aubagio® (Teriflunomide, Genzyme, a Sanofi company) The once-daily pill was approved as a disease-modifying therapy for relapsing forms of MS. Aubagio is the second oral disease-modifying therapy approved for the treatment of MS, and it became available for prescription in October 2012 in the U.S. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6864

Two potential therapies are before FDA

Tysabri® label updated to include lab test to enhance treatment decisions –  The test detects antibodies to the JC virus and can help determine a person's risk of developing PML, a severe brain infection that has emerged in some people who have taken Tysabri (natalizumab, Biogen Idec and Elan). The test should enhance the ability of people with MS to weigh risks and benefits of this therapy. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=5887

Clinical trials discussed at ECTRIMS 2012 – Positive results from trials of statins (cholesterol-reducing medication) and Tysabri in progressive forms of MS, a new approach called AIN457 for treating relapsing MS, and results from phase II and III clinical trials of therapies were among results presented at ECTRIMS focusing on stopping MS. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7052

Phase II results of ocrelizumab in relapsing MS – Experimental ocrelizumab (Genentech), given intravenously, significantly reduced disease activity on MRI scans in a study of 218 people with relapsing-remitting MS. One person died due to brain edema; the relation of this death to the medication is unclear. Additional research, now going on in primary-progressive MS and relapsing-remitting MS, is needed to further determine this therapy's safety and benefits. http://www.nationalmssociety.org/research/research-news/news-detail/index.aspx?nid=5659

Another step toward personalized medicine in MS Harvard researchers discovered that differences in active genes that are detectable in blood samples may be used to group people with MS into categories that predict disease course and response to therapy. Further research is needed, but it represents an early step toward personalized medicine in MS. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6941

New approach to stopping MS Researchers at Northwestern University have developed an innovative strategy for selectively inhibiting the immune attack in MS using tiny "nanoparticles" that were able to reduce disease activity in mice. The team is now planning a phase I clinical trial of this new technology. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7126

Understanding MS

Possible target of immune attacks in some people with MS identified – An immune response to a protein – called "KIR4.1," which is found on several types of brain cells – was observed in the serum of 47% of people with MS. Further research is needed to confirm and understand these findings, which were the result co-funding by the National MS Society. http://nationalmssociety.org/news/news-detail/index.aspx?nid=6619

MS Societies worldwide collaborate to stop MS progression The newly formed International Progressive MS Collaborative published a paper outlining challenges and identifying key research priorities to propel efforts to stop MS progression. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6847

Stress management reduces MS activity A 24-week stress management program reduced disease activity on MRI scans significantly more than in a control group, in a study at Northwestern University involving 121 people with relapsing MS. However, the benefits appeared to disappear after the weekly in-person stress management sessions were completed. Future studies should provide more clarity for optimizing the potential benefits of stress management. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6629

Society launches project to change how MS disability and progression are measured This cross-sector collaboration has the goal of developing new or improved tools that will be able to track benefits of therapies more quickly in people so that new therapies to stop MS progression may be tested using better assessment tools that are accepted by drug regulatory agencies. http://nationalmssociety.org/news/news-detail/index.aspx?nid=6777

Researchers co-funded by the National MS Society discover possible mechanism for MS damage to nerve tissue – The University of California, San Francisco researchers found that a blood-clotting protein called fibrinogen may play an early role in triggering inflammation that damages nerve fibers in a mouse model of MS. This points to a role for fibrinogen in stimulating inflammation by cells called microglia. If confirmed, targeting the interaction of fibrinogen and microglia may prove to be a novel strategy for stopping MS damage in its tracks. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7157

Save this date January 30, 2013, 2:00 – 3:00 p.m. ET and sign up for the live webcast, "From the Frontlines: New Avenues In MS Research for 2013." Visit the National MS Society website.

About Multiple Sclerosis
Multiple sclerosis, an unpredictable, often disabling disease of the central nervous system, interrupts the flow of information within the brain, and between the brain and body.  Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 400,000 people in the U.S. and over 2.1 million worldwide.

About the National Multiple Sclerosis Society
The National MS Society addresses the challenges of each person affected by MS. To fulfill this mission, the Society funds cutting-edge research, drives change through advocacy, facilitates professional education, collaborates with MS organizations around the world, and provides programs and services designed to help people with MS and their families move forward with their lives.  In 2011 alone, through its national office and 50-state network of chapters, the Society devoted $164 million to programs and services that assisted more than one million people. To move us closer to a world free of MS, the Society also invested $40 million to support more than 325 new and ongoing research projects around the world. The Society is dedicated to achieving a world free of MS. Join the movement at www.nationalMSsociety.org.

SOURCE National Multiple Sclerosis Society

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As pervasive as cloud technology is -- and as persuasive as the arguments are for using it -- the cloud has its limits. Some companies will always have security concerns about storing data in the cloud and certain high-transaction applications will always be better suited for on-premises storage. Those statements were among the bottom-line takeaways delivered at Cloud Expo this week, a three day, bi-annual event focused on cloud technologies, adoption and associated challenges.
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
Everyone wants to use containers, but monitoring containers is hard. New ephemeral architecture introduces new challenges in how monitoring tools need to monitor and visualize containers, so your team can make sense of everything. In his session at @DevOpsSummit, David Gildeh, co-founder and CEO of Outlyer, will go through the challenges and show there is light at the end of the tunnel if you use the right tools and understand what you need to be monitoring to successfully use containers in your...
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in compute, storage and networking technologies, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
Join IBM November 2 at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how to go beyond multi-speed it to bring agility to traditional enterprise applications. Technology innovation is the driving force behind modern business and enterprises must respond by increasing the speed and efficiency of software delivery. The challenge is that existing enterprise applications are expensive to develop and difficult to modernize. This often results in what Gartner calls ...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor – all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
“DevOps is really about the business. The business is under pressure today, competitively in the marketplace to respond to the expectations of the customer. The business is driving IT and the problem is that IT isn't responding fast enough," explained Mark Levy, Senior Product Marketing Manager at Serena Software, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...